` ZEAL (Zealand Pharma A/S) vs OMX Copenhagen 25 Comparison - Alpha Spread

ZEAL
vs
OMX Copenhagen 25

Over the past 12 months, ZEAL has underperformed OMX Copenhagen 25, delivering a return of -17% compared to the OMX Copenhagen 25's 8% drop.

Stocks Performance
ZEAL vs OMX Copenhagen 25

Loading
ZEAL
OMX Copenhagen 25
Add Stock

Performance Gap
ZEAL vs OMX Copenhagen 25

Loading
ZEAL
OMX Copenhagen 25
Difference

Performance By Year
ZEAL vs OMX Copenhagen 25

Loading
ZEAL
OMX Copenhagen 25
Add Stock

Competitors Performance
Zealand Pharma A/S vs Peers

OMX Copenhagen 25
ZEAL
ABBV
AMGN
GILD
VRTX
Add Stock

Zealand Pharma A/S
Glance View

Market Cap
40.9B DKK
Industry
Biotechnology

Zealand Pharma A/S is a Danish biotechnology company that has carved a niche in the medical field by focusing on the design and development of innovative peptide-based medicines. Established in 1998 and headquartered in Copenhagen, the company is driven by a singular mission: to improve patients' lives through impactful treatments. Zealand's expertise lies in peptide therapeutics, a compelling segment of biopharmaceuticals due to their ability to mimic biological processes with high specificity and efficacy. The company has a keen focus on addressing unmet medical needs, particularly in the treatment of metabolic and gastrointestinal diseases. With a robust pipeline that ranges from early-stage research to late-stage clinical trials, Zealand Pharma leverages its proprietary technology to discover and develop novel pharmaceuticals that can be game-changers in their respective therapeutic areas. Zealand Pharma's business model centers around the development and commercialization of its proprietary medicines, both independently and through strategic partnerships. By collaborating with larger pharmaceutical companies, Zealand enhances its global commercialization capabilities and mitigates the financial risks inherent in drug development. For instance, the company has partnered with multinational corporations, allowing it to tap into resources for advanced research, regulatory processes, and worldwide distribution systems. Revenue streams are diversified through milestone payments, royalties, and direct sales, ensuring a steady inflow of cash that supports continued innovation. This strategic approach not only sustains its operations but also propels its mission of delivering transformative healthcare solutions. In essence, Zealand Pharma thrives at the confluence of science and strategy, driving both its financial health and its contributions to the biopharmaceutical landscape.

ZEAL Intrinsic Value
94.75 DKK
Overvaluation 84%
Intrinsic Value
Price
Back to Top